I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

IMAB 01.08.2025

Full Press ReleaseSEC FilingsOur IMAB Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
  • 01.06.2025 - I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
  • 12.04.2024 - Piper Sandler 36th Annual Healthcare Conference (In Person)

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]

Chairman of the Board,Wei Fu, informed the Company of his intent to purchase up to$2,000,000of the Company's American Depository Shares (ADSs)

ROCKVILLE, Md.,Jan. 8, 2025/PRNewswire/ --I-Mab(NASDAQ: IMAB) (the "Company"), aU.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the Company has been informed thatWei Fu, the Chairman of the Board, intends to purchase up to$2,000,000of the Company's ADSs in open market transactions. As the planned purchases are to be executed by Wei Fu via his controlled entity,I-Mabcannot guarantee the number of ADSs to be purchased or the time frame in which the ADSs will be bought in the open market.

(PRNewsfoto/I-Mab Biopharma)

Wei Fu, Chairman of the Board ofI-Maband Chief Executive Officer ofCBC Group, said: "The Board of Directors and the Company's senior leadership team successfully executed on the corporate strategy for 2024, and the recent portfolio prioritization aligns with our long-term goal to increase shareholder value."

I-Mabrecently announced a portfolio prioritization positioning givastomig, a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, as its lead clinical program. Data is expected in the early second half of 2025 in a dose escalation study of givastomig in combination with nivolumab plus chemotherapy. Additionally, a 40-patient dose expansion study is now underway, with data expected in early 2026. The Company's current cash runway extends into 2027.

AboutI-Mab

I-Mab(NASDAQ: IMAB) is aU.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer.I-Mabhas established operations in theU.S.inRockville, Maryland, andShort Hills, New Jersey. For more information, please visit us at:https://www.i-mabbiopharma.com/and follow us onLinkedInandX.

I-Mab Forward Looking Statements

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of theU.S.Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "believes", "designed to", "anticipates", "future", "intends", "plans", "potential", "estimates", "confident", and similar terms or the negative thereof.I-Mabmay also make written or oral forward-looking statements in its periodic reports to theU.S. Securities and Exchange Commission(the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements aboutI-Mab'sbeliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company's pipeline; the timing and progress of studies and trials; the potential open market purchases byWei Fu; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following:I-Mab'sability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval ofI-Mab'sdrug candidates;I-Mab'sability to achieve commercial success for its drug candidates, if approved;I-Mab'sability to obtain and maintain protection of intellectual property for its technology and drugs;I-Mab'sreliance on third parties to conduct drug development, manufacturing and other services; andI-Mab'slimited operating history andI-Mab'sability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the "Risk Factors" section inI-Mab'smost recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors inI-Mab'ssubsequent filings with theSEC. All forward-looking statements are based on information currently available toI-Mab.I-Mabundertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

I-Mab Investor & Media Contacts

Tyler EhlerSenior Director, Investor RelationsIR@imabbio.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-announces-open-market-purchases-of-company-american-depositary-shares-by-board-member-302345282.html

SOURCEI-Mab Biopharma

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com